In an era of increasing health challenges and an aging global population, the Chronic Lymphocytic Leukemia (CLL) Market has become more significant than ever. From advancements in treatment options to the rise in research activities, this dynamic market offers substantial opportunities for robust growth. Navigating this complex landscape requires in-depth understanding and a comprehensive knowledge base.
Our market research report offers an unprecedented scrutiny of the CLL market. The report provides detailed insights, including factors contributing to market growth such as the increasing global prevalence of CLL and a rising geriatric population worldwide. It further investigates the sizable product pipeline and growing research activities in this field. Finally, our report also explores the latest market trends and potential barriers to market growth, offering a balanced overview of the industry landscape. It is an indispensable resource for those seeking to understand and capitalize on the opportunities presented by the growing CLL market.
The COVID-19 pandemic has significantly impacted the chronic lymphocytic leukemia market. Cancer treatments such as chemotherapy and immune suppressants damage the patient's immune system. This weakened immune system of the target population is expected to create a risk of COVID-19 infection. Various research has been conducted to find the impact of COVID-19 on CLL patients. According to the research article published by Nature in September 2021, due to immunodeficiency brought on by the illness and its treatment, patients with chronic lymphocytic leukemia (CLL) are more vulnerable to severe infections. And COVID-19 remained to have a high admission rate even among consecutive and young early-stage CLL patients. This is expected to have created a demand for the availability of treatment for CLL drugs and therapies, which is further expected to bolster the studied market growth in the initial phase of the pandemic. However, as the pandemic has subsided currently, the market is expected to have stable growth during the forecast period of the study.
Factors such as the rise in the global prevalence of chronic lymphocytic leukemia coupled with the increasing geriatric population and huge product pipeline, along with growing research activities, are fuelling market growth.
The world is aging with the increasing geriatric population across the countries and creating various disease burdens, including chronic lymphocytic leukemia. The data updated by World Health Organization (WHO) in October 2021 shows that 1 in 6 individuals will be 60 or older by 2030 globally. The number of persons in the globe who are 60 years or older will double by 2050. (2.1 billion). In addition, according to the article published by the American Journal of Hematology in October 2021, the age-adjusted incidence of chronic lymphocytic leukemia (CLL) is 4.9 per 100,000 inhabitants per year, making CLL one of the most common types of leukemia. As per the source above, the median age at diagnosis is 70 years, and only 9.1% of patients with CLL are younger than 45 years. Thus, the increasing geriatric population coupled with the burden of CLL among the target population is expected to create opportunities for CLL treatment. Thereby driving the market growth over the analysis period.
Furthermore, the recent development in CLL treatment has been increasing recently. For instance, in November 2021, as per TG Therapeutics, Inc.’s press release, Food and Drug Administration (FDA) planned to host a meeting of the Oncologic Drugs Advisory Committee (ODAC) in connection with its review of the pending Biologics License Application (BLA)/supplemental New Drug Application (sNDA) for the combination of ublituximab and UKONIQ (umbralisib) (combination referred to as U2) for the treatment of adult patients with Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL). And in December 2021, the TG Therapeutics presented favorable outcomes for patients treated with U2 with co-morbidities or concomitant medications and a retrospective analysis of the Unity-CLL Phase 3 Trial at the American Society of Hematology (ASH) Annual Meeting. Thus, such advances in the market are anticipated to boost the demand for the availability of the CLL treatment, further driving the market growth.
Thus, the studied market is expanding, with the increase in research activities, and is anticipated to witness growth over the forecast period. However, the higher cost of the patented drugs and therapy is expected to restrain the growth of the market growth over the forecast period.
Chronic Lymphocytic Leukemia Market Trends
Parenteral Route of Administration Segment is Expected to Witness a Healthy Growth Over the Forecast PeriodThe parenteral route of the administration segment is expected to witness growth in recent years and is expected to do so over the forecast period. This dominance is due to their rapid absorption and onset of action, along with their availability in various routes such as intravenous, subcutaneous, intrathecal, or intramuscular routes according to the patient's need.
The data updated by the National Library of Medicine in February 2022, the parenteral route of administration can be done in three different ways such as intravenous injections, intramuscular and subcutaneous injections, among which intravenous injection is the common parental route of administration due to its benefit of bypassing the first-pass metabolism by the liver. Given their superficial location on the skin, peripheral veins provide easy access to the circulatory system and are often utilized in the parenteral administration of medications. Similarly, Ascendia Pharmaceuticals data updated in 2022 stated that the quickest and second-most popular method of drug delivery is parenteral formulation development for medications given by injection or infusion. Additionally, as per the Ascendia Pharmaceuticals data updated in 2022, a major benefit of parenteral administration is that it can provide a rapid onset of action and rapid absorption of the drug. Thus, such benefits and advantages of the parenteral route of administration of the segment is anticipated to grow over the forecast period.
Furthermore, more number of approved drugs available drugs for parenteral administration for the treatment of chronic lymphocytic leukemia (CLL) is one of the factors affecting segment growth. As per data medically reviewed by Drugs.com in April 2022, Bendamustine Hydrochloride Injection is indicated for treating patients with CLL with a recommended dose of 100 mg/m2 administered intravenously over 30 minutes on Days 1 and 2 of a 28-day cycle, up to 6 cycles. Thus, such instances are predicted to bolster market growth in the future.
Therefore, owing to the factors above, the studied segment is anticipated to show growth over the forecast period.
North America is expected to Hold a Significant Share in the Market During the Forecast PeriodNorth America is anticipated to witness growth over the forecast period and dominate the market. The United States is leading the market due to high healthcare expenditure, research and development activities, and a rising prevalence of leukemia. Additionally, the rising geriatric population across the United States is the primary driver for the United States CLL market.
The data updated by the American Cancer Society in 2022, nearly 60,650 new cases of leukemia (all kinds) are estimated to be diagnosed in 2022, among which chronic lymphocytic leukemia (CLL) accounts for approximately 20,160 new cases. Additionally, as per the source mentioned above, about 1/4th of newly diagnosed cases of leukemia is CLL. The lifetime chance of developing CLL is approximately 1 in 175 (0.57%) for the average person. Most people with CLL are older individuals, typically of age 70 years old, when they receive a diagnosis. In addition, the data updated in February 2022 by HealthyPeople.gov shows that the population in the United States is aging unprecedently, and the population aged 65 or older is projected to reach 23.5% (98 million) by 2060 in the country. Thus, with the increasing geriatric population in the country, the risk of CLL is also rising. This is expected to generate demand for the availability of drugs and therapy for the disease for treatment. Hence, the studied market is anticipated to grow over the forecast period.
Moreover, the increasing research and development of various treatment options in the country are anticipated to drive market growth over the forecast period. For instance, in September 2021, Triplet therapy developed by researchers at the Dana-Farber Cancer Institute showed promise in a phase 2 study in chronic lymphocytic leukemia. As per the trial results, 86% of the trial participants demonstrated a significant response throughout the two-year study, and no Minimal Residual Disease (MRD) could be detected in these patients’ bone marrow using sensitive cellular tests, which is a key predictor of survival without progression.
Therefore, owing to the factors mentioned above, North America is predicted to witness growth over the forecast period.
Chronic Lymphocytic Leukemia Market Competitor AnalysisThe Chronic Lymphocytic Leukemia Market is moderately consolidated and consists of several major players. A few of the key players are developing biosimilars to the existing chemotherapies, while others are launching generic products trending in the market. Few key players are entering into partnerships to develop and increase their market position globally. Some of the companies which are currently dominating the market are F. Hoffmann-La Roche Ltd, AstraZeneca plc, Verastem Inc, Novartis AG, and AbbVie Inc., among others.
Additional benefits of purchasing the report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1.2 Scope of the Study
4.2 Market Drivers
4.2.1 Rise in Global Prevalence of Chronic Lymphocytic Leukemia Coupled With the Increasing Geriatric Population
4.2.2 Huge Product Pipeline along with Growing Research Activities
4.3 Market Restraints
4.3.1 Higher Cost of the Patented Drugs and Therapies
4.3.2 Side Effects Associated with Chemotherapy
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.2 By Treatment
5.3 By Distribution Channel
5.3.2 Speciality Clinics
5.4.1 North America
188.8.131.52 United states
184.108.40.206 United Kingdom
220.127.116.11 Rest of Europe
18.104.22.168 South Korea
22.214.171.124 Rest of Asia-Pacific
5.4.4 Middle East and Africa
126.96.36.199 South Africa
188.8.131.52 Rest of Middle East and Africa
5.4.5 South America
184.108.40.206 Rest of South America
6.1.1 F. Hoffmann-La Roche Ltd
6.1.3 Secura Bio, Inc
6.1.4 Novartis AG
6.1.5 AbbVie, Inc.
6.1.6 Gilead Sciences, Inc.
6.1.7 BeiGene, Inc.
6.1.8 Sanofi (Genzyme Corporation)
6.1.9 Ziopharm Oncology Inc
6.1.10 Ono pharmaceuticals Co Ltd
6.1.11 Teva Pharmaceutical Industries
A selection of companies mentioned in this report includes:
- F. Hoffmann-La Roche Ltd
- Secura Bio, Inc
- Novartis AG
- AbbVie, Inc.
- Gilead Sciences, Inc.
- BeiGene, Inc.
- Sanofi (Genzyme Corporation)
- Ziopharm Oncology Inc
- Ono pharmaceuticals Co Ltd
- Teva Pharmaceutical Industries